Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score

References

• Feuerlein K., Zucca E., Ghielmini M. First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 2009;50:325–334.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Imrie KR, Friedlich J, . The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psychooncology 2009;18:554–559
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, . High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, . Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma – results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004;104:2667–2674.
   PubMed Web of Science ®Google Scholar
• Gyan E, Foussard C, Bertrand P, . High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009;113:995–1001.
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, . Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006;108:2540–2544.
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza FR Jr, Bajorunaite R, . Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521–3529.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, . Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460–1468.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, . Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Stewart D, Voralia M, Chaudhry A, . A prospective phase II comparison of autologous (ASCT) or allogeneic (ALLOSCT) blood stem cell transplantation for indolent B-cell non-Hodgkin lymphoma (NHL) using RICE reinduction, then high dose fludarabine and busulfan conditioning. Ann Oncol 2008;19(Suppl. 4):iv184–185, Abstract 345.
   Google Scholar
• Montoto S, Canals C, Rohatiner AZS, . Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007;21:2324–2331.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Gordon LI, King J, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443–468.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Nadler L, Davies AJ, . Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007;25:2554–2559.
   PubMed Web of Science ®Google Scholar
• Kornacker M, Stumm J, Pott C, . Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 2009;20:722–728.
   PubMed Web of Science ®Google Scholar
• Hicks LK, Woods A, Buckstein R, . Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43:701–708.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Loberiza FR, . Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008;14:36–42.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Montanari F, Alessandrino EP, . Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remissions in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008;19:1331–1335.
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, . Prospective, mulitcenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004–4013.
   PubMed Web of Science ®Google Scholar
• Kang TY, Rybicki LA, Bolwell BJ, . Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007;40:973–978.
   PubMed Web of Science ®Google Scholar
• Sebban C, Brice P, Delarue R, . Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614–3620.
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Dreger P. Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 2010;51: 967–974.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Tonnissen E, Van Glabbeke M, . BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 2010;28:2246–2252.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rohatiner AZ, Matthews J, . Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica 2010;95:1130–1135.
   PubMed Web of Science ®Google Scholar
• Lunning M, Armitage JO. The curability of follicular lymphoma. Transfus Apher Sci 2007;37:31–35.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, . Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460–1468.
   PubMed Web of Science ®Google Scholar
• Brown JR, Feng Y, Gribben JG, . Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007;13:1057–1065.
   PubMed Web of Science ®Google Scholar
• Tarella C, Ladetto M, Benedetti F, . A recent update of three consecutive prospective trials with high dose therapy and autograft, without or with rituximab, as primary treatment for advanced stage follicular lymphoma (FL) shows a sizeable group of patients surviving in continuous complete remission up to 16 years after the end of treatment: should we still consider FL an incurable disease? Blood 2009;114(Suppl. 1): Abstract 882.
   Google Scholar
• Tarella C, Zanni M, Magni M, . Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. J Clin Oncol 2008;26:3166–3175.
   PubMed Web of Science ®Google Scholar
• Laudi N, Arora M, Burns LJ, . Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11: 129–135.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schmitz N, Gisselbrecht C, . Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010;28(15 Suppl.): Abstract 8005.
   Google Scholar